Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 2,100 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 2,100 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $56.52, for a total value of $118,692.00. Following the sale, the insider owned 291,439 shares in the company, valued at $16,472,132.28. The trade was a 0.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Michael Chi also recently made the following trade(s):

• On Wednesday, September 17th, Michael Chi sold 13,749 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.50, for a total value of $694,324.50.
• On Monday, September 15th, Michael Chi sold 4,150 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.00, for a total value of $232,400.00.
• On Thursday, July 24th, Michael Chi sold 2,100 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.52, for a total value of $120,792.00.
• On Wednesday, July 23rd, Michael Chi sold 13,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.00, for a total value of $770,000.00.

Hims & Hers Health Stock Performance

HIMS opened at $58.35 on Friday. The business has a fifty day simple moving average of $51.22 and a 200 day simple moving average of $46.35. The company has a market capitalization of $13.19 billion, a PE ratio of 72.93, a price-to-earnings-growth ratio of 3.71 and a beta of 2.14. Hims & Hers Health, Inc. has a 1 year low of $16.05 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the prior year, the firm earned $0.06 earnings per share. Hims & Hers Health’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the second quarter valued at $26,000. Quaker Wealth Management LLC bought a new stake in Hims & Hers Health during the second quarter valued at about $29,000. Bessemer Group Inc. grew its holdings in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the period. Skandinaviska Enskilda Banken AB publ grew its holdings in Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock valued at $37,000 after purchasing an additional 600 shares during the period. Finally, Spire Wealth Management bought a new stake in Hims & Hers Health during the second quarter valued at about $42,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HIMS. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group reissued a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.